[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Arnold, M., Sierra, M.S., Laversanne, M., et al. (2017) Global Patterns and Trends in Colorectal Cancer Incidence and Mortality. Gut, 66, 683-691. https://doi.org/10.1136/gutjnl-2015-310912
|
[3]
|
Garcia, J., Hurwitz, H.I., Sandler, A.B., et al. (2020) Bevaci-zumab (Avastin®) in Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook. Cancer Treatment Reviews, 86, Article ID: 102017.
https://doi.org/10.1016/j.ctrv.2020.102017
|
[4]
|
Alfonso, P.G. (2018) Chemotherapy plus Bevacizumab as Neoad-juvant or Conversion Treatment in Patients with Colorectal Liver Metastases. Anticancer Research, 38, 3069-3077. https://doi.org/10.21873/anticanres.12564
|
[5]
|
钱健, 秦超, 殷长军. 肿瘤靶向药物疗效及毒性与基因多态性间相关性的研究进展[J]. 中国肿瘤外科杂志, 2012, 4(3): 161-163.
|
[6]
|
Simanshu, D.K., Nissley, D.V. and McCor-mick, F. (2017) RAS Proteins and Their Regulators in Human Disease. Cell, 170, 17-33. https://doi.org/10.1016/j.cell.2017.06.009
|
[7]
|
Salomon, D.S., Brandt, R., Ciardiello, F., et al. (1995) Epidermal Growth Factor-Related Peptides and Their Receptors in Human Malignancies. Critical Reviews in Oncology/Hematology, 19, 183-232.
https://doi.org/10.1016/1040-8428(94)00144-I
|
[8]
|
Parseghian, C.M., Napolitano, S., Loree, J.M., et al. (2019) Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clinical Cancer Research, 25, 6899-6908. https://doi.org/10.1158/1078-0432.CCR-19-0823
|
[9]
|
Parseghian, C.M., Loree, J.M., Morris, V.K., et al. (2019) Anti-EGFR-Resistant Clones Decay Exponentially after Progression: Implications for Anti-EGFR Re-Challenge. Annals of Oncology, 30, 243-249.
https://doi.org/10.1093/annonc/mdy509
|
[10]
|
Rowland, A., Dias, M.M., Wiese, M.D., et al. (2015) Meta-Analysis of BRAF Mutation as a Predictive Biomarker of Benefit from Anti-EGFR Monoclonal Antibody Therapy for RAS Wild-Type Metastatic Colorectal Cancer. British Journal of Cancer, 112, 1888-1894. https://doi.org/10.1038/bjc.2015.173
|
[11]
|
De Roock, W., Claes, B., Bernasconi, D., et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA Mutations on the Efficacy of Cetuximab plus Chemotherapy in Chemotherapy-Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis. The Lancet Oncology, 11, 753-762. https://doi.org/10.1016/S1470-2045(10)70130-3
|
[12]
|
Sakata, S. and Larson, D.W. (2022) Targeted Therapy for Colorectal Cancer. Surgical Oncology Clinics of North America, 31, 255-264. https://doi.org/10.1016/j.soc.2021.11.006
|
[13]
|
Bhattacharya, S. (2023) An Empirical Review on the Resistance Mechanisms of Epidermal Growth Factor Receptor Inhibitors and Predictive Molecular Biomarkers in Colorectal Cancer. Critical Reviews in Oncology/Hematology, 183, Article ID: 103916. https://doi.org/10.1016/j.critrevonc.2023.103916
|
[14]
|
Kawai, S., Takeshima, N., Hayasaka, Y., et al. (2021) Com-parison of Irinotecan and Oxaliplatin as the First-Line Therapies for Metastatic Colorectal Cancer: A Meta-Analysis. BMC Cancer, 21, Article No. 116.
https://doi.org/10.1186/s12885-021-07823-7
|
[15]
|
Cremolini, C., Antoniotti, C., Lonardi, S., et al. (2018) Activity and Safety of Cetuximab plus Modified FOLFOXIRI Followed by Maintenance with Cetuximab or Bevacizumab for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. JAMA Oncology, 4, 529-536.
https://doi.org/10.1001/jamaoncol.2017.5314
|
[16]
|
Modest, D.P., Martens, U.M., Riera-Knorrenschild, J., et al. (2019) FOLFOXIRI plus Panitumumab as First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). Journal of Clinical Oncology, 37, 3401-3411. https://doi.org/10.1200/JCO.19.01340
|
[17]
|
Amodio, V., Yaeger, R., Arcella, P., et al. (2020) EGFR Blockade Re-verts Resistance to KRAS(G12C) Inhibition in Colorectal Cancer. Cancer Discovery, 10, 1129-1139. https://doi.org/10.1158/2159-8290.CD-20-0187
|
[18]
|
Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., et al. (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. The New England Journal of Medicine, 359, 1757-1765.
https://doi.org/10.1056/NEJMoa0804385
|
[19]
|
Shin, A.E., Giancotti, F.G. and Rustgi, A.K. (2023) Metastatic Col-orectal Cancer: Mechanisms and Emerging Therapeutics. Trends in Pharmacological Sciences, 44, 222-236. https://doi.org/10.1016/j.tips.2023.01.003
|
[20]
|
Tan, L., Tran, B., Tie, J., et al. (2023) A Phase Ib/II Trial of Com-bined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib in Combination Trial) Study. Clinical Cancer Research, 29, 1017-1030. https://doi.org/10.1158/1078-0432.CCR-22-3094
|
[21]
|
Dinu, I.M., Mihăilă, M., Diculescu, M.M., et al. (2023) Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice. Medicina (Kaunas), 59, Article No. 350. https://doi.org/10.3390/medicina59020350
|
[22]
|
Rosen, L.S., Jacobs, I.A. and Burkes, R.L. (2017) Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology, 12, 599-610. https://doi.org/10.1007/s11523-017-0518-1
|
[23]
|
Carmeliet, P. and Jain, R.K. (2011) Principles and Mechanisms of Vessel Normalization for Cancer and Other Angiogenic Diseases. Nature Reviews Drug Discovery, 10, 417-427. https://doi.org/10.1038/nrd3455
|
[24]
|
Mariotti, V., Fiorotto, R., Cadamuro, M., et al. (2021) New Insights on the Role of Vascular Endothelial Growth Factor in Biliary Pathophysiology. JHEP Reports, 3, Article ID: 100251. https://doi.org/10.1016/j.jhepr.2021.100251
|
[25]
|
Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004) Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. The New England Journal of Medicine, 350, 2335-2342.
https://doi.org/10.1056/NEJMoa032691
|
[26]
|
Cremolini, C., Antoniotti, C., Rossini, D., et al. (2020) Upfront FOLFOXIRI plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 plus Bevacizumab Followed by FOLFIRI plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial. The Lancet Oncology, 21, 497-507. https://doi.org/10.1016/S1470-2045(19)30862-9
|
[27]
|
Grothey, A., Van Cutsem, E., Sobrero, A., et al. (2013) Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicen-tre, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 381, 303-312. https://doi.org/10.1016/S0140-6736(12)61900-X
|
[28]
|
Creasy, J.M., Sadot, E., Koerkamp, B.G., et al. (2018) The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Co-lon Cancer. Annals of Surgical Oncology, 25, 431-438.
https://doi.org/10.1245/s10434-017-6264-x
|
[29]
|
Tabernero, J., Yoshino, T., Cohn, A.L., et al. (2015) Ramu-cirumab versus Placebo in Combination with Second-Line FOLFIRI in Patients with Metastatic Colorectal Carcinoma That Progressed during or after First-Line Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE): A Randomised, Double-Blind, Multicentre, Phase 3 Study. The Lancet Oncology, 16, 499-508. https://doi.org/10.1016/S1470-2045(15)70127-0
|
[30]
|
Valverde, A., Peñarando, J., Cañas, A., et al. (2015) Simul-taneous Inhibition of EGFR/VEGFR and Cyclooxygenase-2 Targets Stemness-Related Pathways in Colorectal Cancer Cells. PLOS ONE, 10, e131363.
https://doi.org/10.1371/journal.pone.0131363
|
[31]
|
Ahcene, D.S., Daniel, F., Milani, A., et al. (2022) HER2 in Colorectal Cancer: The Long and Winding Road from Negative Predictive Factor to Positive Actionable Target. American Society of Clinical Oncology Educational Book, 42, 1-14.
|
[32]
|
Yonesaka, K., Zejnullahu, K., Okamoto, I., et al. (2011) Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. Science Translational Medicine, 3, 86r-99r.
https://doi.org/10.1126/scitranslmed.3002442
|
[33]
|
Bertotti, A., Migliardi, G., Galimi, F., et al. (2011) A Molecu-larly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 1, 508-523. https://doi.org/10.1158/2159-8290.CD-11-0109
|
[34]
|
Matallanas, D., Birtwistle, M., Romano, D., et al. (2011) Raf Family Kinases: Old Dogs Have Learned New Tricks. Genes Cancer, 2, 232-260. https://doi.org/10.1177/1947601911407323
|
[35]
|
Davies, H., Bignell, G.R., Cox, C., et al. (2002) Mutations of the BRAF Gene in Human Cancer. Nature, 417, 949-954.
https://doi.org/10.1038/nature00766
|
[36]
|
Kopetz, S., Desai, J., Chan, E., et al. (2015) Phase II Pilot Study of Vemurafenib in Patients with Metastatic BRAF-Mutated Colorectal Cancer. Journal of Clinical Oncology, 33, 4032-4038.
https://doi.org/10.1200/JCO.2015.63.2497
|
[37]
|
Kopetz, S., Guthrie, K.A., Morris, V.K., et al. (2021) Randomized Trial of Irinotecan and Cetuximab with or without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of Clinical Oncology, 39, 285-294. https://doi.org/10.1200/JCO.20.01994
|
[38]
|
Wang, Z., Qin, B.D., Ye, C.Y., et al. (2022) Cetuximab and Vemurafenib plus FOLFIRI (5-Fluorouracil/Leucovorin/ Irinotecan) for BRAF V600E-Mutated Advanced Colorectal Cancer (Improvement): An Open-Label, Single-Arm, Phase II Trial. Euro-pean Journal of Cancer, 163, 152-162. https://doi.org/10.1016/j.ejca.2021.12.028
|
[39]
|
Corcoran, R.B., Atreya, C.E., Falchook, G.S., et al. (2015) Combined BRAF and MEK Inhibition with Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. Journal of Clinical Oncology, 33, 4023-4031.
https://doi.org/10.1200/JCO.2015.63.2471
|
[40]
|
Chen, L. (2004) Co-Inhibitory Molecules of the B7-CD28 Family in the Control of T-Cell Immunity. Nature Reviews Immunology, 4, 336-347. https://doi.org/10.1038/nri1349
|
[41]
|
Le, D.T., Uram, J.N., Wang, H., et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine, 372, 2509-2520. https://doi.org/10.1056/NEJMoa1500596
|
[42]
|
Sherman, E., Lee, J.L., Debruyne, P.R., et al. (2023) Safety and Ef-ficacy of Cobimetinib plus Atezolizumab in Patients with Solid Tumors: A Phase II, Open-Label, Multicenter, Multico-hort Study. ESMO Open, 8, Article ID: 100877.
https://doi.org/10.1016/j.esmoop.2023.100877
|
[43]
|
Overman, M.J., Lonardi, S., Wong, K., et al. (2018) Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. Journal of Clinical Oncology, 36, 773-779. https://doi.org/10.1200/JCO.2017.76.9901
|
[44]
|
Sawayama, H., Miyamoto, Y., Ogawa, K., et al. (2020) Investiga-tion of Colorectal Cancer in Accordance with Consensus Molecular Subtype Classification. Annals of Gastroenterologi-cal Surgery, 4, 528-539.
https://doi.org/10.1002/ags3.12362
|
[45]
|
Motta, R., Cabezas-Camarero, S., Torres-Mattos, C., et al. (2021) Immu-notherapy in Microsatellite Instability Metastatic Colorectal Cancer: Current Status and Future Perspectives. Journal of Clinical and Translational Research, 7, 511-522.
|
[46]
|
Weng, J., Li, S., Zhu, Z., et al. (2022) Exploring Immunotherapy in Colorectal Cancer. Journal of Hematology & Oncology, 15, Article No. 95. https://doi.org/10.1186/s13045-022-01294-4
|